Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.

Andrologia - 1 Feb 2022

Shiota Masaki, Fujimoto Naohiro, Sekino Yohei, Tsukahara Shigehiro, Nagakawa Shohei, Takamatsu Dai, Abe Tatsuro, Kinoshita Fumio, Ueda Shohei, Ushijima Miho, Matsumoto Takashi, Kashiwagi Eiji, Inokuchi Junichi, Uchiumi Takeshi, Oda Yoshinao, Eto Masatoshi

Abstract excerpt

This study aimed to investigate the significance of HSD3B1 gene status including germline polymorphism and somatic alterations in prostate cancer. Patients with prostate cancer treated with androgen-deprivation therapy, as well as tissues from metastatic prostate cancer, were included. Genomic DNA was extracted from cancer tissues and whole blood samples, and HSD3B1 (rs1047303, 1245C) was genotyped by Sanger...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Multienzyme Complexes

Share to Polymorphism, Genetic

Share to Prostatic Neoplasms, Castration-Resistant

Source

Identifiers

PMID: 34747051
DOI: 10.1111/and.14307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.PMID 34747051Read ↗

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and BeyondSemantic proximity Read ↗

Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.Semantic proximity Read ↗

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.Semantic proximity Read ↗

Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer.Semantic proximity Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.Semantic proximity Read ↗

Adrenal-Permissive HSD3B1 Genotype-An Invisible Stimulator of Prostate Cancer Mortality.Semantic proximity Read ↗

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity Read ↗

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.Semantic proximity Read ↗

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.Semantic proximity Read ↗

Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.